Cancer proteomics: from bench to bedside

Cancer proteomics: from bench to bedside

Daoud, S.S.

114,35 €(IVA inc.)

This book provides the reader with broad perspectives and breadth of knowledge on current topics related to the use of proteomic strategies in cancer therapy as well as anticipated challenges that may arise from its application in daily practice. The book is divided into 4 parts. The first part begins with thecurrent technologies used in proteomics that allow for protein profiling and for the identification of druggable targets in human samples. Mass spectrometry based protein characterization and protein microarrays hold great promise ofpredicting response to specific drugs in cancer therapy. The second part deals with the use proteomics in cell signaling. At the present, the pharmaceutical and biotechnology industries have many potentially useful small molecule inhibitors of many pathways important in cancer that have yet to be taken to clinical trials. Comprehensive look at the use of proteomic strategies in cancer therapy Covers all the latest technologies used in proteomics Includes in-depthinformation on the human proteome and the role of the FDA in regulating the use of proteomics The latest research on proteomics and tyrosine kinases p53 signalling and tumor biomarkers INDICE: Current and emerging mass spectrometry instrumentation and methodsfor proteomic analyses.- Integration of genomics and proteomics in dissectingp53 signaling.- Proteomic profiling of tyrosine kinases as pharmacological endpoints for targeted cancer therapy.- Oncoproteomics for personalized management of cancer.- Application of serum and tissue proteomics to understand and detect solid tumors.- Insight on renal cell carcinoma proteome.- Proteomics in lung cancer.- Proteomic strategies of therapeutic individualization and target discovery in acute myeloid leukemia.- New tumor biomarkers: Practical considerations prior to clinical application.- Annotating the human proteome: From establishing a parts list to a tool for target identification.- Regulatory aspects of the oncology drug-diagnostics co-development process by proteomics approach.

  • ISBN: 978-1-58829-858-4
  • Editorial: HUMANA PRESS
  • Encuadernacion: Cartoné
  • Páginas: 279
  • Fecha Publicación: 01/01/2008
  • Nº Volúmenes: 1
  • Idioma: Inglés